Vaccine

Moderna Named a Top Employer by Science for Tenth Consecutive Year

CAMBRIDGE, MA / ACCESSWIRE / October 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top…

1 year ago

Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe 2024

CHATHAM, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage…

1 year ago

Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will present…

1 year ago

Soligenix, Inc. to Present at the 2024 ThinkEquity Conference

PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company…

1 year ago

BuzzRx® Introduces Vaccination Scheduling Functionality

Tool Helps Customers Find and Schedule Vaccine Appointments at CVS Pharmacy FORT LAUDERDALE, Fla., Oct. 22, 2024 /PRNewswire/ -- BuzzRx, a free…

1 year ago

Dotmatics Introduces Luma Antibody & Protein Engineering Solution for End-to-End Antibody Discovery

The first in a series of Dotmatics Luma Multimodal R&D Solutions Geneious has been seamlessly composed into Luma showcasing cross-therapeutic…

1 year ago

PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine

Study to evaluate PDS01ADC + Xtandi® (Enzalutamide) versus Xtandi® alone to be presented by Dr. Ravi Madan, National Cancer Institute…

1 year ago

Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184

Company to conduct a Phase 1 Drug-Drug Interaction StudyPhase 2 filing on track for Q1 2025 SOUTH SAN FRANCISCO, Calif.,…

1 year ago

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Determined the high dose of OCU410ST to be the maximum tolerated doseNo serious adverse events have been reportedApproved proceeding to…

1 year ago